title: kappa-opioids induce a reversible inhibition of CFU-GM from CD133(+) cord blood cells.
abstract: BACKGROUND
  Opioid agonists have been shown to exert an inhibitory action on a number of malignant and non-malignant cell types. However, there are no reports dealing with their effect on hemopoietic progenitors. Based upon our previous experience of opioid agonists we examined whether opioids could interfere with the growth of CFU-GM from CD133(+) cord blood cells.
  
  
  METHODS
  Cord blood samples were subjected to CD133(+) column selection, with subsequent exposure to opioid agonists and antagonists or both, in semi-solid cultures for CFU-GM growth. Colonies of day 7 of culture were replated in fresh medium in the absence of opioids. The colonies were evaluated at 7 and 14 days of culture. RT-PCR was performed for the detection of opioid and somatostatin receptors. Apoptosis tests and immunophenotypic evaluations were employed in liquid cultures in conditions identical to those of the semi-solid ones.
  
  
  CONCLUSIONS
  Our results suggest that opioids can induce a significant inhibition of CFU-GM growth, which is reversible and not mediated through opioid or somatostatin receptors, while apoptosis is not implicated. Whether this finding could be used for clinical intervention remains to be examined.
authors.affiliation: Department of Pediatric Hematology-Oncology, University of Crete Medical School, Heraklion, Crete, Greece. lena@med.uoc.gr
authors.forename: H
authors.initials: H
authors.lastname: Dimitriou
authors.forename: E
authors.initials: E
authors.lastname: Bakogeorgou
authors.forename: M
authors.initials: M
authors.lastname: Kampa
authors.forename: G
authors.initials: G
authors.lastname: Notas
authors.forename: E
authors.initials: E
authors.lastname: Stiakaki
authors.forename: E
authors.initials: E
authors.lastname: Kouroumalis
authors.forename: M
authors.initials: M
authors.lastname: Kalmanti
authors.forename: E
authors.initials: E
authors.lastname: Castanas
mesh_terms: D000071916:AC133 Antigen; D000701:Analgesics, Opioid / Q000819:agonists / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D015703:Antigens, CD / Q000378:metabolism*; D017209:Apoptosis; D002478:Cells, Cultured; D005260:Female; D005312:Fetal Blood / Q000166:cytology*; D006023:Glycoproteins / Q000378:metabolism*; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000187:drug effects* / Q000502:physiology*; D006801:Humans; D016130:Immunophenotyping; D010455:Peptides / Q000378:metabolism*; D017473:Receptors, Opioid, kappa / Q000235:genetics / Q000378:metabolism*; D017481:Receptors, Somatostatin / Q000235:genetics / Q000378:metabolism
chemical_list: D000071916:AC133 Antigen; D000701:Analgesics, Opioid; D015703:Antigens, CD; D006023:Glycoproteins; C000606023:PROM1 protein, human; D010455:Peptides; D017473:Receptors, Opioid, kappa; D017481:Receptors, Somatostatin